Your browser doesn't support javascript.
loading
Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.
Kim, Sung-Hyun; Menon, Hari; Jootar, Saengsuree; Saikia, Tapan; Kwak, Jae-Yong; Sohn, Sang-Kyun; Park, Joon Seong; Jeong, Seong Hyun; Kim, Hyeoung Joon; Kim, Yeo-Kyeoung; Oh, Suk Joong; Kim, Hawk; Zang, Dae Young; Chung, Joo Seop; Shin, Ho Jin; Do, Young Rok; Kim, Jeong-A; Kim, Dae-Young; Choi, Chul Won; Park, Sahee; Park, Hye Lin; Lee, Gong Yeal; Cho, Dae Jin; Shin, Jae Soo; Kim, Dong-Wook.
Afiliación
  • Kim SH; Dong-A University Medical Center, Busan, South Korea.
  • Menon H; Tata Memorial Hospital, Parel, Mumbai, India.
  • Jootar S; Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Saikia T; Prince Aly Khan Hospital, Mazagaon, Mumbai, India.
  • Kwak JY; Chonbuk National University Medical School & Hospital, Jeonju, South Korea.
  • Sohn SK; Kyungpook National University Hospital, Daegu, South Korea.
  • Park JS; Ajou University Hospital, Suwon, South Korea.
  • Jeong SH; Ajou University Hospital, Suwon, South Korea.
  • Kim HJ; Chonnam National University, Hwasun Hospital, Hwasun, South Korea.
  • Kim YK; Chonnam National University, Hwasun Hospital, Hwasun, South Korea.
  • Oh SJ; Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Kim H; Ulsan University Hospital, Ulsan, South Korea.
  • Zang DY; Hallym University Sacred Heart Hospital, Anyang, South Korea.
  • Chung JS; Pusan National University Hospital, Pusan, South Korea.
  • Shin HJ; Pusan National University Hospital, Pusan, South Korea.
  • Do YR; Dongsan Medical Center, Keimyung University, Daegu, South Korea.
  • Kim JA; St. Vincent Hospital, The Catholic University of Korea, Suwon, South Korea.
  • Kim DY; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Choi CW; Korea University, Guro Hospital, Seoul, South Korea.
  • Park S; Cancer Research Institute, The Catholic University of Korea, Seoul, South Korea.
  • Park HL; Central Research Institute, IL-YANG Pharm. Co. Ltd., Yongin, South Korea.
  • Lee GY; Central Research Institute, IL-YANG Pharm. Co. Ltd., Yongin, South Korea.
  • Cho DJ; Central Research Institute, IL-YANG Pharm. Co. Ltd., Yongin, South Korea.
  • Shin JS; Central Research Institute, IL-YANG Pharm. Co. Ltd., Yongin, South Korea.
  • Kim DW; Cancer Research Institute, The Catholic University of Korea, Seoul, South Korea Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea dwkim@catholic.ac.kr.
Haematologica ; 99(7): 1191-6, 2014 Jul.
Article en En | MEDLINE | ID: mdl-24705186
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide de Fase Crónica / Proteínas de Fusión bcr-abl / Resistencia a Antineoplásicos / Inhibidores de Proteínas Quinasas / Antineoplásicos Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Año: 2014 Tipo del documento: Article País de afiliación: Corea del Sur
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide de Fase Crónica / Proteínas de Fusión bcr-abl / Resistencia a Antineoplásicos / Inhibidores de Proteínas Quinasas / Antineoplásicos Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Año: 2014 Tipo del documento: Article País de afiliación: Corea del Sur